Business Office Feature


See allHide authors and affiliations

Science  09 Apr 2010:
Vol. 328, Issue 5975, pp. 249
DOI: 10.1126/science.328.5975.249


It's an interesting time for genome scientists. With next generation technologies outpacing Moore's Law and prices plummeting, human genomes-once multimillion-dollar propositions-today cost tens of thousands of dollars, about the same as a car. Yet multiply those prices by the sample numbers required to triangulate disease genes-not to mention the burden of collecting, storing, and analyzing the resulting data-and expect genomic sticker shock. There is an alternative. Supported by some $76.5 million in federal spending since 2008, plus a clutch of commercial products, exome sequencing proved its mettle in 2009 with a trio of papers highlighting its clinical possibilities. No wonder Science named exome studies one of five "areas to watch" in its December "Breakthrough of the Year" issue.

Stay Connected to Science